Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naporafenib and Trametinib in NRAS-mutant melanoma
NCT06346067Phase 3Active, not recruiting
- Sponsor
- Erasca
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of naporafenib in cutaneous melanoma (CM), sponsored by Erasca. Started Apr 2024; status: active, not recruiting.
02
Drugs
naporafenib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT06346067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346067.